CN110520444A - 用于制备多特异性抗体的多肽接头 - Google Patents

用于制备多特异性抗体的多肽接头 Download PDF

Info

Publication number
CN110520444A
CN110520444A CN201880009175.5A CN201880009175A CN110520444A CN 110520444 A CN110520444 A CN 110520444A CN 201880009175 A CN201880009175 A CN 201880009175A CN 110520444 A CN110520444 A CN 110520444A
Authority
CN
China
Prior art keywords
ser
gly
val
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880009175.5A
Other languages
English (en)
Chinese (zh)
Inventor
E.朱科夫斯基
O.莱格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayomunix Pharmaceutical
Biomunex Pharmaceuticals
Original Assignee
Bayomunix Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayomunix Pharmaceutical filed Critical Bayomunix Pharmaceutical
Publication of CN110520444A publication Critical patent/CN110520444A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880009175.5A 2017-01-09 2018-01-09 用于制备多特异性抗体的多肽接头 Pending CN110520444A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305022 2017-01-09
EP17305022.0 2017-01-09
PCT/EP2018/050481 WO2018127608A1 (en) 2017-01-09 2018-01-09 A polypeptide linker for preparing multispecific antibodies

Publications (1)

Publication Number Publication Date
CN110520444A true CN110520444A (zh) 2019-11-29

Family

ID=57984856

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880009175.5A Pending CN110520444A (zh) 2017-01-09 2018-01-09 用于制备多特异性抗体的多肽接头

Country Status (13)

Country Link
US (2) US11958913B2 (de)
EP (1) EP3565847A1 (de)
JP (2) JP2020503873A (de)
KR (1) KR102589422B1 (de)
CN (1) CN110520444A (de)
AU (1) AU2018206229B2 (de)
BR (1) BR112019014147A2 (de)
CA (1) CA3052084A1 (de)
IL (1) IL267886B1 (de)
MX (1) MX2019008241A (de)
SG (1) SG11201906313SA (de)
WO (1) WO2018127608A1 (de)
ZA (1) ZA201905160B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724986A (zh) * 2022-07-11 2023-03-03 惠和生物技术(上海)有限公司 三特异性抗体及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
US12054550B2 (en) 2016-04-28 2024-08-06 Biomunex Pharmaceuticals Bispecific antibodies targeting EGFR and HER2
SG11201906313SA (en) * 2017-01-09 2019-08-27 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
CN111094355A (zh) 2017-03-27 2020-05-01 拜奥穆尼克斯制药 稳定的多特异性抗体
WO2020136566A1 (en) 2018-12-24 2020-07-02 Sanofi Multispecific binding proteins with mutant fab domains

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013005194A2 (en) * 2011-07-07 2013-01-10 Centre National De La Recherche Scientifique Multispecific antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020093029A (ko) * 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
RU2349340C2 (ru) * 2002-10-10 2009-03-20 Мерк Патент Гмбх Биспецифические антитела к erb-b и их применение для лечения опухолей
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2009097325A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
DK2771022T3 (da) * 2011-10-11 2020-09-28 Viela Bio Inc Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
BR112015009070A2 (pt) * 2012-10-23 2017-07-04 Statens Seruminstitut proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
DE102014213460B4 (de) * 2014-07-10 2022-10-20 Bayerische Motoren Werke Aktiengesellschaft Klappenanordnung für ein Kraftfahrzeug
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
PL3313441T3 (pl) * 2015-06-24 2024-08-19 Janssen Biotech, Inc. Immunomodulacja i leczenie guzów litych przeciwciałami swoiście wiążącymi cd38
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
US12054550B2 (en) 2016-04-28 2024-08-06 Biomunex Pharmaceuticals Bispecific antibodies targeting EGFR and HER2
SG11201906313SA (en) * 2017-01-09 2019-08-27 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
CN111094355A (zh) 2017-03-27 2020-05-01 拜奥穆尼克斯制药 稳定的多特异性抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013005194A2 (en) * 2011-07-07 2013-01-10 Centre National De La Recherche Scientifique Multispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSÉE GOLAY ET AL.,: ""Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies"", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115724986A (zh) * 2022-07-11 2023-03-03 惠和生物技术(上海)有限公司 三特异性抗体及其用途
WO2024012457A1 (zh) * 2022-07-11 2024-01-18 惠和生物技术(上海)有限公司 三特异性抗体及其用途
CN115724986B (zh) * 2022-07-11 2024-07-19 惠和生物技术(上海)有限公司 三特异性抗体及其用途

Also Published As

Publication number Publication date
KR20190102271A (ko) 2019-09-03
WO2018127608A1 (en) 2018-07-12
AU2018206229B2 (en) 2024-09-19
EP3565847A1 (de) 2019-11-13
RU2019125228A3 (de) 2021-04-22
ZA201905160B (en) 2021-05-26
AU2018206229A1 (en) 2019-08-29
BR112019014147A2 (pt) 2020-02-11
JP2020503873A (ja) 2020-02-06
RU2019125228A (ru) 2021-02-09
CA3052084A1 (en) 2018-07-12
MX2019008241A (es) 2019-12-09
IL267886B1 (en) 2024-07-01
US20240209118A1 (en) 2024-06-27
SG11201906313SA (en) 2019-08-27
IL267886A (en) 2019-09-26
KR102589422B1 (ko) 2023-10-13
US11958913B2 (en) 2024-04-16
JP2023027215A (ja) 2023-03-01
US20190330377A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
CN110520444A (zh) 用于制备多特异性抗体的多肽接头
EP3448890B1 (de) Bispezifische antikörper gegen egfr und her2
CN109476741B (zh) 与cd38和pd-l1结合的分子
CA3057567C (en) Stable multispecific antibodies
CN111349163B (zh) 针对cd123的单克隆抗体
AU2018346264A1 (en) Cysteine engineered antigen-binding molecules
RU2776302C2 (ru) Полипептидный линкер для получения мультиспецифических антител
RU2779602C2 (ru) Устойчивые мультиспецифические антитела

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination